Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

53.08 -0.01 (-0.02%)
Streaming Delayed Price Updated: 1:20 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 445,929
Open 53.70
Bid (Size) 53.07 (3)
Ask (Size) 53.10 (3)
Prev. Close 53.09
Today's Range 52.73 - 53.87
52wk Range 50.27 - 69.83
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024
INCY stock results show that Incyte missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-18.90%
-18.90%
1 Month
-4.93%
-4.93%
3 Month
-10.28%
-10.28%
6 Month
-1.65%
-1.65%
1 Year
-21.99%
-21.99%

More News

Read More
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Don't overlook NASDAQ:INCY—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Via Benzinga
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Via Benzinga
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
Via Chartmill
NASDAQ:INCY, a growth stock which is not overvalued.
Via Chartmill
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
From Incyte and Escient Pharmaceuticals
Via Business Wire
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
From Incyte
Via Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
Via Chartmill
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
Via InvestorPlace
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
From Incyte Corporation
Via Business Wire
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
From Incyte
Via Business Wire
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Via InvestorPlace
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
From Incyte
Via Business Wire
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.